Loading…
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-100M | $-105M | $-82M | -34.4% | -100.0% | 159.6% |
| 2024 | $22M | $-39M | $-40M | $-42M | -27.8% | -11.5% | 81.6% |
| 2023 | $25M | $-23M | $-22M | $-28M | -98.6% | 886.8% | -23.2% |
| 2022 | $3M | $-29M | $-29M | $2M | -246.2% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 2.55 | 25.18 | 22.27 | 0 |
| Operating Revenue | - | 2.55 | 25.18 | 22.27 | 0 |
| Operating Expense | - | 32.25 | 49.26 | 64.83 | 108.14 |
| Research And Development | - | 21.82 | 36.45 | 49.97 | 84.45 |
| Selling General And Administration | - | 10.32 | 12.37 | 14.21 | 22.75 |
| Total Expenses | - | 32.25 | 49.26 | 64.83 | 108.14 |
| Operating Income | - | -29.70 | -24.08 | -42.56 | -108.14 |
| Total Operating Income As Reported | - | -29.70 | -24.08 | -42.56 | -108.14 |
| EBITDA | - | -29.16 | -23.01 | -39.04 | -100.11 |
| Normalized EBITDA | - | -29.65 | -24.73 | -41.13 | -106.21 |
| EBIT | - | -29.70 | -24.08 | -40.47 | -102 |
| Interest Expense | - | - | - | 0 | 3.05 |
| Net Interest Income | - | - | - | 0 | -3.05 |
| Other Non Operating Income Expenses | - | 0.19 | 0.07 | 0.01 | 0.05 |
| Other Income Expense | - | 0.68 | 1.79 | 2.10 | 6.15 |
| Interest Expense Non Operating | - | - | - | 0 | 3.05 |
| Net Non Operating Interest Income Expense | - | - | - | 0 | -3.05 |
| Pretax Income | - | -29.02 | -22.29 | -40.47 | -105.04 |
| Tax Provision | - | - | - | 0 | 0 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -29.02 | -22.29 | -40.47 | -105.04 |
| Net Income From Continuing And Discontinued Operation | - | -29.02 | -22.29 | -40.47 | -105.04 |
| Net Income From Continuing Operation Net Minority Interest | - | -29.02 | -22.29 | -40.47 | -105.04 |
| Net Income | - | -29.02 | -22.29 | -40.47 | -105.04 |
| Net Income Common Stockholders | - | -29.02 | -22.29 | -40.47 | -105.04 |
| Net Income Including Noncontrolling Interests | - | -29.02 | -22.29 | -40.47 | -105.04 |
| Normalized Income | - | -29.51 | -24.01 | -42.56 | -111.14 |
| Diluted NI Availto Com Stockholders | - | -29.02 | -22.29 | -40.47 | -105.04 |
| Basic Average Shares | - | 24.55 | 26.78 | 35.22 | 46.48 |
| Diluted Average Shares | - | 24.55 | 26.78 | 35.22 | 46.48 |
| Reconciled Depreciation | - | 0.53 | 1.07 | 1.43 | 1.89 |
| Total Unusual Items | - | 0.49 | 1.72 | 2.09 | 6.10 |
| Total Unusual Items Excluding Goodwill | - | 0.49 | 1.72 | 2.09 | 6.10 |
| Special Income Charges | - | -0.03 | -0.01 | -0.11 | -0.16 |
| Other Special Charges | -0.32 | - | - | - | - |
| Gain On Sale Of Security | - | 0.52 | 1.73 | 2.20 | 6.26 |
| Depreciation Amortization Depletion Income Statement | - | 0.11 | 0.44 | 0.65 | 0.94 |
| Depreciation And Amortization In Income Statement | - | 0.11 | 0.44 | 0.65 | 0.94 |
| General And Administrative Expense | - | 10.32 | 12.37 | 14.21 | 22.75 |
| Other Gand A | - | 3.38 | 3.19 | 3.61 | 7.22 |
| Salaries And Wages | - | 6.94 | 9.18 | 10.61 | 15.53 |
| Gain On Sale Of Ppe | - | -0.03 | -0.01 | -0.11 | -0.16 |
| Depreciation Income Statement | - | 0.11 | 0.44 | 0.65 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Capricor Therapeutics, Inc.this co. | CAPR | $1.6B | -15.41 | 5.29 | -34.4% | -13.44 |
| Palvella Therapeutics, Inc. | PVLA | $1.6B | -39.48 | 58.85 | -149.1% | -44.28 |
| Innoviva, Inc. | INVA | $1.6B | 6.03 | 1.39 | 23.1% | 3.66 |
| Fortrea Holdings Inc. | FTRE | $1.6B | - | 2.90 | -175.0% | - |
| Tyra Biosciences, Inc. | TYRA | $1.6B |
| - |
| - |
| - |
| - |
| - |
| - |
| -13.48 |
| 6.24 |
| -46.3% |
| -11.68 |
| Syndax Pharmaceuticals, Inc. | SNDX | $1.6B | -5.59 | 24.71 | -441.6% | -7.18 |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.6B | -10.99 | 5.21 | -47.4% | -8.97 |
| agilon health, inc. | AGL | $1.6B | - | 12.54 | -308.8% | - |
| Nurix Therapeutics, Inc. | NRIX | $1.6B | - | 2.93 | -49.1% | - |
| Peer Median | - | -10.99 | 5.72 | -99.1% | -8.97 | |